Carcinoid Tumors
📧 Sign up to get email alerts when something new happens for Carcinoid Tumors.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-09FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
FDA documents a supplemental approval application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the safety of 68Ga-DOTA-tyr3-Octreotide PET in diagnosing solid tumors has completed with posted results…
-
CLINICAL_TRIALS trial_result · 2020-12-21Clinical Trial Update: Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating Ga-68 DOTATOC PET-CT imaging in the management of neuroendocrine tumors has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]
Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors [Phase 2]
Phase II study of pertuzumab in combination with erlotinib for metastatic or unresectable neuroendocrine tumors was terminated, with results…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-01-31Clinical Trial Update: A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors [Phase 2]
A Phase 2 clinical trial update on sunitinib plus lanreotide versus placebo plus lanreotide in patients with progressive advanced/metastatic…
-
FDA approval · 2014-01-30FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation. Th…
-
FDA approval · 2013-11-12FDA Approved: OCTREOTIDE ACETATE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' Original Application for octreotide acetate injectable, a generic form of octreotide. It is approved fo…
-
CLINICAL_TRIALS trial_result · 2011-05-06Clinical Trial Update: Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors [Phase 2]
A Phase 2 study evaluating SOM230 (pasireotide) in patients with metastatic carcinoid tumors has completed and results were posted.